<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355910</url>
  </required_header>
  <id_info>
    <org_study_id>SGU-05</org_study_id>
    <nct_id>NCT04355910</nct_id>
  </id_info>
  <brief_title>Intermittent Fasting in Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Effects of Intermittent and Continuous Calorie Restriction on Body Weight and Metabolism in Adults With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaoguan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaoguan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although preliminary evidence suggests that intermittent fasting mimic-diet (IFD) exerts
      stronger effects on body weight and metabolic parameters, which may link obesity,
      non-alcoholic fatty liver disease (NAFLD) and major chronic diseases, compared with
      continuous calorie restriction (CCR), there is a lack of well-powered intervention studies.
      This randomized controlled trial will test whether IFD, operationalized as the &quot;5:2 diet,&quot;
      has stronger effects on anthropometric and body composition characteristics, and circulating
      metabolic biomarkers than CCR and a control regimen in adults with NAFLD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The patient is represented in code</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>Change from baseline body weight at week 8</time_frame>
    <description>Change of body weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>Change from baseline plasma TG, TC and LDL at week 8</time_frame>
    <description>Plasma lipids levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>Change from baseline plasma glucose and insulin at week 8</time_frame>
    <description>Plasma glucose and insulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>Change from baseline plasma bile acids and the gut microbiome at week 8</time_frame>
    <description>Changes of blood metabolites and the gut microbiome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intermittent Fasting</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <condition>Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>Intermittent fasting mimic-diet (IFD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Restrict 75% energy on two non-consecutive days each week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous calorie restriction (CCR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A daily 25% energy-restricted Mediterranean-type diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No advice to restrict energy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Calorie restriction</intervention_name>
    <description>Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.
The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).
The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat.</description>
    <arm_group_label>Continuous calorie restriction (CCR)</arm_group_label>
    <arm_group_label>Intermittent fasting mimic-diet (IFD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosed criteria of fatty liver by ultrasound were presence of two of the three
             following criteria: increased hepatic echogenicity compared with cortical of the right
             kidney, blurring of liver vasculature, and deep attenuation of the ultrasonographic
             signal.

        Exclusion Criteria:

          -  Excessive alcohol consumption (ethanol &gt; 140 g/wk for men and &gt; 70 g/wk for women),
             cirrhosis, viral hepatitis, cardiovascular disease, cancer, any consumption of
             nonsteroidal anti-inflammatory drugs, corticosteroids or prescriptive medicine that
             affect liver function, lipid and glucose metabolism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangdong Medical University</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523808</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiwen Zhang, M. D.</last_name>
      <phone>86-769-22896572</phone>
      <email>313743920@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Xuebin Gao, M. D.</last_name>
      <phone>86-18819747104</phone>
      <email>401779114@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peiwen Zhang, M. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Honghui Guo, Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

